Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation

References

• Rubin B, Palestine A G. Complications of corticosteroid and immuno-suppressive drugs. Int Ophthalmol Clin 1989; 29: 159–171
   PubMedGoogle Scholar
• Nussenblatt R. The expanding use of immunosuppression in the treatment of non-infectious ocular disease. J Autoimmunol 1992; 5: 247–257
   PubMed Web of Science ®Google Scholar
• Nussenblatt R B, Palestine A G, Chan C -C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96: 275–281
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115: 763–769
   PubMed Web of Science ®Google Scholar
• Palestine A G, Austin H A, Balow J E, et al. Renal histopathologic alterations in patients treated with cyclosporin for uveitis. N Engl J Med 1986; 314: 1293–1298
   PubMed Web of Science ®Google Scholar
• Paul A A, Leeper H F, Friberg T R. CMV retinitis and the use of FK 506. Transplant Proc 1991; 23: 3042–3043
   PubMedGoogle Scholar
• Roberge F G, Xu D, Chan C C, de Smet M D, Nussenblatt R B, Chen H. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 1993; 12: 197–203
   PubMed Web of Science ®Google Scholar
• Roberge F G, Kozhich A, Chan C -C, Martin D F, Nussenblatt R B, de Smet M D. Inhibition of cellular transfer of experimental autoimmune uveoretinitis by Rapamycin. Ocular Immunol Inflamm 1993; 1: 269–273
   PubMedGoogle Scholar
• Kahan B D, Gibbons S, Tejpal N, Stepkowski S M, Chou T C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232–239
   PubMed Web of Science ®Google Scholar
• Sigal N H, Dumont F, Cyclosporin J. A. FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519–560
   PubMed Web of Science ®Google Scholar
• Bierer B E, Manila P S, Standaert R F, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK 506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231–9235
   PubMed Web of Science ®Google Scholar
• Dumont F J, Staruch M J, Koprak S L, Melino M R, Sigal N H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251–258
   PubMed Web of Science ®Google Scholar
• Emmel E A, Verweij C L, Durand D B, Higgins E L, Crabtree G R. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989; 246: 1617
   PubMed Web of Science ®Google Scholar
• Tocci M J, Matkovich D A, Collier K A, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718–726
   PubMed Web of Science ®Google Scholar
• Northrop J P, Crabtree G R, Mattila P S. Negative regulation of interleukin 2 transcription by the glucocorticoid receptor. J Exp Med 1992; 175: 1235–1245
   PubMed Web of Science ®Google Scholar
• Dumont F J, Melino M R, Staruch M J, Koprak S L, Fischer P A, Sigal N H. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418–1424
   PubMed Web of Science ®Google Scholar
• de Kozak Y, Sakai J, Thillaye B, Faure J P. S-antigen-induced experimental autoimmune uveoretinitis in rats. Curr Eye Res 1981; 1: 327–337
   PubMed Web of Science ®Google Scholar
• Gery I, Mochizuki M, Nussenblatt R B. Retinal specific antigens and immunopathogenic processes they provoke. Progr Retinal Res 1986; 575–109
   Google Scholar
• Chou T -C, Talalay P. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207–216
   PubMedGoogle Scholar
• Chou T -C, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55
   PubMedGoogle Scholar
• Chou T -C. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and Antagonism in Chemotherapy, T -C Chou, D C Rideout. Academic Press, San Diego 1991; 61–102
   Google Scholar
• Roberge F G, Xu D, Chan C -C. A new effective and non-harmful chemical adjuvant for the induction of experi mental autoimmune uveoretinitis. Curr Eye Res 1992; 11: 371–376
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Nussenblatt R B, Kuwabara T, Gery I. Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1985; 26: 226–232
   PubMed Web of Science ®Google Scholar
• Roberge F G, Lorberboum-Galski H, Le Hoang P, et al. Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol 1989; 143: 3498–3502
   PubMed Web of Science ®Google Scholar
• Fleisher L N, Ferrell J B, McGahan M C. Synergistic uveitic effects of tumor necrosis factor-alpha and interleukin-1 beta. Invest Ophthalmol Vis Sci 1992; 33: 2120–2127
   PubMed Web of Science ®Google Scholar
• Richardson N A, Chamberlain C G, Mc Avoy J W. IGF-1 enhancement of FGF-induced lens fiber differentiation in rats of different ages. Invest Ophthalmol Vis Sci 1993; 34: 3303–3312
   PubMed Web of Science ®Google Scholar
• Crow J M, Lima P H, Agapitos P J, Nelson J D. Effects of insulin and EGF on DNA synthesis in bovine endothelial cultures: flow cytometric analysis. Invest Ophthalmol Vis Sci 1994; 35: 128–133
   PubMed Web of Science ®Google Scholar
• Berenbaum M C. Synergy, additivism and antagonism in immunosuppres sion. A critical review. Clin Exp Immunol 1977; 28: 1–18
   PubMed Web of Science ®Google Scholar
• Martin D F, DeBarge L R, Nussenblatt R B, Chan C -C, Roberge F G. Synergistic effect of Rapamycin and Cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922–927
   PubMed Web of Science ®Google Scholar
• Whiting P H, Woo J, Adam B J, Hasan N U, Davidson R J, Thomson A W. Toxicity of rapamycin-a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat. Transplantation 1991; 52: 203–208
   PubMed Web of Science ®Google Scholar
• Akselband Y, Harding M W, Nelson P A. Rapamycin inhibits spontaneous and fibroblast growth factor betastimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 2833–2836
   PubMed Web of Science ®Google Scholar
• Appiah A P, Hirose T. Secondary causes of premacular fibrosis. Ophthalmology 1988; 96: 389–392
   Web of Science ®Google Scholar
• Baker H, Sidorowicz A, Sehgal S N, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978; 31: 539–545
   PubMed Web of Science ®Google Scholar